Evidence map›Paper›PMID 28118521›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2017

Brief Report: Treatment of Tumor Necrosis Factor-Transgenic Mice With Anti-Tumor Necrosis Factor Restores Lymphatic Contractions, Repairs Lymphatic Vessels, and May Increase Monocyte/Macrophage Egress.

Echoe M Bouta, Igor Kuzin, Karen de Mesy Bentley, Ronald W Wood, Homaira Rahimi, Rui-Cheng Ji, Christopher T Ritchlin, Andrea Bottaro, Lianping Xing, Edward M Schwarz

Abstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. The Function ofbioRxiv : the preprint server for biology · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Echoe M BoutaUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Igor KuzinCooper Medical School of Rowan University, Camden, New Jersey.
Karen de Mesy BentleyUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Ronald W WoodUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Homaira RahimiUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Rui-Cheng JiOita University, Oita, Japan.
Christopher T RitchlinUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Andrea BottaroCooper Medical School of Rowan University, Camden, New Jersey.
Lianping XingUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Edward M SchwarzUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
University of Rochester · USCooper Medical School of Rowan University · USOita University · JP

Funding

Role of B Cells in Synovial Inflammation & LN Remodeling in RA ArthritisP01AI078907 · NIAID · UNIVERSITY OF ROCHESTER · PI LUND, FRANCES E. · 2010 to 2014
$10.8M
Project-004U54CA260563 · NCI · EMORY UNIVERSITY · PI DHODAPKAR, MADHAV V, SANZ, IGNACIO E. · 2020 to 2024
$10.2M
Rochester Resource-Based Center for Bone, Muscle and Orthopaedic Research (ROCSTARR) (Overall Application)P30AR069655 · NIAMS · UNIVERSITY OF ROCHESTER · PI Edward M. Schwarz · 2016 to 2026
$7.8M
Elucidating the Mechanisms of Arthritic Flare and Developing TreatmentsR01AR056702 · NIAMS · UNIVERSITY OF ROCHESTER · PI SCHWARZ, EDWARD M. · 2009 to 2025
$4.9M
A Model System for the Study of Human B-cell ToleranceR37AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2010 to 2019
$3.7M
Training in Orthopaedic Researchhttps://apps.era.nih.gov/grantfolder/viewInternalGF.era?applId=8841318&folderId=90T32AR053459 · NIAMS · UNIVERSITY OF ROCHESTER · PI ZUSCIK, MICHAEL J · 2006 to 2017
$3.4M
Role of TNFalpha in Osteoclast-Mediated Bone LossR01AR048697 · NIAMS · UNIVERSITY OF ROCHESTER · PI XING, LIANPING · 2002 to 2012
$2.6M
DC-STAMP: Regulator of Osteoclastogenesis and Response Marker in PsAR01AR069000 · NIAMS · UNIVERSITY OF ROCHESTER · PI RITCHLIN, CHRISTOPHER TREVOR · 2016 to 2020
$1.7M
Study of osteoblast regulation in TNF-mediated bone lossR01AR063650 · NIAMS · UNIVERSITY OF ROCHESTER · PI XING, LIANPING · 2013 to 2016
$1.4M
sGC beta1: A Potential Critical Regulator of the Lymphatic Pulse and Novel Target in Arthritic FlareK08AR067885 · NIAMS · UNIVERSITY OF ROCHESTER · PI RAHIMI, HOMAIRA · 2016 to 2020
$844k
NCI NIH HHS U54 CA260563NIAID NIH HHS P01 AI078907NIAID NIH HHS R37 AI049660NIAMS NIH HHS K08 AR067885NIAMS NIH HHS P30 AR069655NIAMS NIH HHS R01 AR048697NIAMS NIH HHS R01 AR056702NIAMS NIH HHS R01 AR063650NIAMS NIH HHS R01 AR069000NIAMS NIH HHS T32 AR053459
6 · The paper itself

Abstract

objectiveRecent studies have demonstrated that there is an inverse relationship between lymphatic egress and inflammatory arthritis in affected joints. As a model, tumor necrosis factor (TNF)-transgenic mice develop advanced arthritis following draining lymph node (LN) collapse, and loss of lymphatic contractions downstream of inflamed joints. It is unknown if these lymphatic deficits are reversible. This study was undertaken to test the hypothesis that anti-TNF therapy reduces advanced erosive inflammatory arthritis, associated with restoration of lymphatic contractions, repair of damaged lymphatic vessels, and evidence of increased monocyte egress.

methodsTNF-transgenic mice with advanced arthritis and collapsed popliteal LNs were treated with anti-TNF monoclonal antibody (10 mg/kg weekly) or placebo for 6 weeks, and effects on knee synovitis, lymphatic vessel ultrastructure and function, and popliteal LN cellularity were assessed by ultrasound, histology, transmission electron microscopy (TEM), near-infrared indocyanine green imaging, and flow cytometry.

resultsAnti-TNF therapy significantly decreased synovitis (∼5-fold; P < 0.05 versus placebo), restored lymphatic contractions, and significantly increased the number of popliteal LN monocyte/macrophages (∼2-fold; P < 0.05 versus placebo). TEM demonstrated large activated macrophages attached to damaged lymphatic endothelium in mice with early arthritis, extensively damaged lymphatic vessels in placebo-treated mice with advanced arthritis, and rolling leukocytes in repaired lymphatic vessels in mice responsive to anti-TNF therapy.

conclusionThese findings support the concept that anti-TNF therapy ameliorates erosive inflammatory arthritis, in part via restoration of lymphatic vessel contractions and potential enhancement of inflammatory cell egress.

Indexed as

AnimalsAntibodies, MonoclonalArthritis, ExperimentalArthritis, RheumatoidFlow CytometryLymphatic VesselsLymph NodesMacrophagesMaleMiceMice, TransgenicMonocytesSynovitisTreatment OutcomeTumor Necrosis Factor-alphaAntibodies, MonoclonalTumor Necrosis Factor-alpha

Identifiers

PMID28118521
PMCPMC5449211
OpenAlexW2737814603

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.